Stockscreener 앱 받기
52.91
1.21%
-0.74
전일 마감가:
$53.65
열려 있는:
$53.57
하루 거래량:
889.37K
Relative Volume:
0.32
시가총액:
$10.60B
수익:
$2.83B
순이익/손실:
$-1.02B
주가수익비율:
-9.6025
EPS:
-5.51
순현금흐름:
$194.14M
1주 성능:
+0.88%
1개월 성능:
-5.83%
6개월 성능:
-5.69%
1년 성능:
+25.44%
1일 변동 폭
$52.83
$53.94
1주일 범위
$50.09
$57.40
52주 변동 폭
$39.97
$72.83
이그젝트 사이 Stock (EXAS) Company Profile
명칭
Exact Sciences Corp
전화
608-284-5700
주소
5505 ENDEAVOR LANE, MADISON, WI
EXAS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EXAS
Exact Sciences Corp
|
52.91 | 10.60B | 2.83B | -1.02B | 194.14M | -5.51 |
|
TMO
Thermo Fisher Scientific Inc
|
403.07 | 156.49B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
196.15 | 145.01B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
533.14 | 42.30B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
117.48 | 34.24B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
156.79 | 27.64B | 15.50B | 1.33B | 2.16B | 7.34 |
이그젝트 사이 Stock (EXAS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-10 | 개시 | Mizuho | Outperform |
| 2025-03-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2025-01-23 | 개시 | Barclays | Overweight |
| 2024-08-28 | 개시 | Wells Fargo | Overweight |
| 2024-06-27 | 개시 | Scotiabank | Sector Outperform |
| 2024-06-03 | 재개 | Jefferies | Buy |
| 2024-01-02 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2023-12-14 | 개시 | Guggenheim | Buy |
| 2023-12-13 | 개시 | Wolfe Research | Outperform |
| 2023-10-10 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-09-28 | 개시 | Bernstein | Outperform |
| 2023-08-02 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2023-05-10 | 업그레이드 | Craig Hallum | Hold → Buy |
| 2023-05-05 | 개시 | UBS | Neutral |
| 2023-03-09 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-02-10 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2023-01-18 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2022-10-19 | 다운그레이드 | Craig Hallum | Buy → Hold |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-06-03 | 개시 | Piper Sandler | Neutral |
| 2021-11-03 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2021-07-29 | 재확인 | BTIG Research | Buy |
| 2021-07-29 | 재확인 | Canaccord Genuity | Buy |
| 2021-07-29 | 재확인 | Oppenheimer | Outperform |
| 2021-07-29 | 재확인 | Stifel | Buy |
| 2021-06-15 | 개시 | Raymond James | Strong Buy |
| 2021-06-03 | 개시 | Goldman | Buy |
| 2021-05-25 | 개시 | Wells Fargo | Equal Weight |
| 2021-01-28 | 개시 | Truist | Buy |
| 2020-10-29 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-10-28 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-10-08 | 재개 | BTIG Research | Buy |
| 2020-04-02 | 개시 | Evercore ISI | Outperform |
| 2020-01-10 | 재개 | BTIG Research | Buy |
| 2020-01-07 | 개시 | Citigroup | Buy |
| 2019-12-13 | 개시 | Dougherty & Company | Buy |
| 2019-11-15 | 개시 | Stifel | Buy |
| 2019-10-17 | 재확인 | BofA/Merrill | Buy |
| 2019-10-01 | 재개 | Craig Hallum | Buy |
| 2019-09-26 | 개시 | Oppenheimer | Outperform |
| 2019-02-26 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-10-09 | 개시 | UBS | Buy |
| 2018-09-05 | 재개 | The Benchmark Company | Hold |
| 2018-08-13 | 재확인 | Canaccord Genuity | Buy |
| 2018-04-03 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2018-01-29 | 개시 | Goldman | Neutral |
| 2018-01-08 | 재확인 | The Benchmark Company | Buy |
| 2017-11-13 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2017-11-01 | 다운그레이드 | BTIG Research | Buy → Neutral |
모두보기
이그젝트 사이 주식(EXAS)의 최신 뉴스
Inside Wisconsin: Cancer tests continue to propel Exact Sciences, even in a skeptical age - hngnews.com
Tom Still: Cancer tests continue to propel Exact Sciences, even in time of research cuts - La Crosse Tribune
Insider Sell: Katherine Zanotti Sells Shares of Exact Sciences Corp (EXAS) - GuruFocus
Exact Sciences Shareholders Approve New Incentive Plan By Investing.com - Investing.com Canada
Exact Sciences Shareholders Approve New Incentive Plan - Investing.com
Exact Sciences Corp (EXAS) Shares Gap Down to $53.95 on Jun 12 - GuruFocus
Molecular Diagnostics for Cancer Market Research 2025: Advances in Personalized Medicine and Liquid Biopsies Reshape Industry Landscape - GlobeNewswire Inc.
Colorectal Cancer Screening Market Deep Research Report - openPR.com
Rhumbline Advisers Acquires 3,873 Shares of Exact Sciences Co. (NASDAQ:EXAS) - Defense World
Hologic Climbs 13% in a Month: How Should You Play the Stock? - Yahoo Finance
Exact Sciences Co. (NASDAQ:EXAS) Stock Position Increased by GAMMA Investing LLC - Defense World
Should You Continue to Hold EXAS Sciences Stock in Your Portfolio? - Yahoo Finance
Global Colorectal Cancer Screening and Diagnostics Market to Reach $46.1 Billion by 2029 - The Malaysian Reserve
Corporate Wellness News from PRNEWSWIRE - Corporate Wellness Magazine
Exact Sciences at William Blair Conference: Vision for Cancer Eradication - Investing.com
Transcript : Exact Sciences Corporation Presents at 45th Annual William Blair Growth Stock Conference, Jun-03-2025 08 - marketscreener.com
Exact Sciences (EXAS): Company Profile, Stock Price, News, Rankings - Fortune
Exact Sciences Announces Expanded Clinical Validation of the Oncodetect™ Test and Molecular Residual Disease Innovation Roadmap - Business Wire
Exact Sciences Clears Technical Benchmark, Hitting 80-Plus RS Rating - inkl
Exact Sciences Announces Expanded Clinical Validation Of Oncodetect Test And Molecular Residual Disease Innovation Roadmap - marketscreener.com
Exact Sciences to present new positive data on Oncodetect in colorectal cancer - TipRanks
Exact Sciences (EXAS) Unveils Advanced MRD Test Data for Colorectal Cancer | EXAS Stock News - GuruFocus
Exact Sciences Announces Expanded Clinical Validation of the Onc - GuruFocus
Exact Sciences Announces Expanded Clinical Validation of the Oncodetect™ Test and Molecular Residual Disease Innovation Roadmap | EXAS Stock News - GuruFocus
Exact Sciences management to meet with Oppenheimer - TipRanks
Upcoming Meeting for Investors with Oppenheimer Highlights EXAS | EXAS Stock News - GuruFocus
Exact Sciences to Participate in June Investor Conference | EXAS Stock News - GuruFocus
Exact Sciences to Participate in June Investor Conference - New Castle News
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Sells 2,099 Shares of Exact Sciences Co. (NASDAQ:EXAS) - Defense World
Exact Sciences Highlights Innovations in Early Cancer Detection - GuruFocus
Exact Sciences Highlights Innovations in Early Cancer Detection and Precision Oncology at ASCO 2025 - Business Wire
WisBusiness: the Show with Kevin Boggs of Medical College of Wisconsin - WisBusiness
Exact Sciences Corporation (EXAS) Slid on Fear of Competition - Insider Monkey
Comerica Bank Lowers Position in Exact Sciences Co. (NASDAQ:EXAS) - Defense World
EXAS Q1 Earnings Call: Outperformance Driven by Commercial Execution, New Products, and Margin Expansion - Yahoo Finance
10 High PE Stocks Insiders Are Buying - Insider Monkey
Exact Sciences at Bank of America 2025 Healthcare Conference: Strategic Growth and Innovation - Investing.com
Transcript : Exact Sciences Corporation Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 10 - marketscreener.com
2 Brilliant Stocks to Buy With $200 and Hold for 5 Years - AOL.com
Exact Sciences Co. (NASDAQ:EXAS) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Exact Sciences Earns 2025 Great Place To Work® Certification™ - Business Wire
Functional Genomics Market Top PlayersExact Sciences - openPR.com
Exact Sciences Announces First-Quarter 2025 Results - ADVFN
Exact Sciences (NASDAQ:EXAS) Price Target Raised to $75.00 - Defense World
Analysts Have Made A Financial Statement On Exact Sciences Corporation's (NASDAQ:EXAS) First-Quarter Report - Yahoo
Exact Sciences Corporation (NASDAQ:EXAS) Q1 2025 Earnings Call Transcript - Insider Monkey
Decoding Exact Sciences Corp (EXAS): A Strategic SWOT Insight - GuruFocus
Exact Sciences Corp Reports Strong Start to 2025 - TipRanks
Exact Sciences (EXAS) Target Price Raised by Barclays to $75 | EXAS Stock News - GuruFocus
Exact Sciences (EXAS) Price Target Raised by RBC Capital | EXAS Stock News - GuruFocus
Exact Sciences: Q1 Earnings Snapshot - GMToday.com
이그젝트 사이 (EXAS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.64%
1.35%
자본화:
|
볼륨(24시간):